Approximately 2,000 US cases of malaria are diagnosed annually. Without appropriate treatment, about 15 percent become severe. Mortality from untreated severe malaria (particularly cerebral malaria) approaches 100 percent.
On Tuesday, the Food and Drug Administration (FDA) approved Artesunate for Injection to Amivas, a Maryland company specializing in treatments for rare and neglected tropical diseases.
Joining me today to talk about severe malaria and the newly approved drug is Bryan Smith, MD. Dr. Smith is the Chief Medical Officer at Amivas.